3 ms·
> As for Shkreli--he's an asshole, but it makes no sense to focus narrowly on isolated abuses. I take it nobody in your family was affected by the price of a D
by criddell 10y ago
> As for Shkreli--he's an asshole, but it makes no sense to focus narrowly on isolated abuses.
I take it nobody in your family was affected by the price of a Daraprim tablet going from around $10 to $700 per pill?
> The big problem here is that manufacturers of generics have almost zero ability to invest in even minimal R&D.
Because that's not what they do. That's like complaining that Belkin makes lightning cables and they aren't even investing in developing new computers.
- rayiner 10y ago> I take it nobody in your family was affected by the price of a Daraprim tablet going from around $10 to $700 per pill? No, but I buy Epipens for my daughter. That fact is, of course, irrelevant. Systems shouldn't be designed by hyper-focusing on corner cases.
- criddell 10y agoIt's not irrelevant nor is it much of a corner case. I too buy Epipens. The nice thing about corner cases is that sometimes they are the tip of the proverbial iceberg. Maybe a market solution only fails in a couple of corner cases or maybe there's a fundamental problem with trying to apply market solutions to something like healthcare.